ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AveXis, the gene-therapy subsidiary of Novartis, is being investigated by the US Food and Drug Administration for manipulating data related to its recently approved gene therapy Zolgensma. AveXis told the FDA about the manipulation on June 28, a month after the $2.1 million drug was approved, even though the firm knew about it before the approval. The data relate to the weights and life spans of mice that AveXis used while refining its production process. Since the manipulation is unrelated to evidence of the therapy’s efficacy, the FDA says Zolgensma should remain on the market, although it warns that Novartis may face legal consequences.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter